• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    FOXM1 coming of age: time for translation into clinical benefits? 
    •   QMRO Home
    • Institute of Dentistry
    • Centre for Oral Immunobiology and Regenerative Medicine
    • FOXM1 coming of age: time for translation into clinical benefits?
    •   QMRO Home
    • Institute of Dentistry
    • Centre for Oral Immunobiology and Regenerative Medicine
    • FOXM1 coming of age: time for translation into clinical benefits?
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    FOXM1 coming of age: time for translation into clinical benefits?

    View/Open
    Teh FOXM1 coming of age: time for translation into clinical benefits? 2012 Published.pdf (971.8Kb)
    Volume
    2
    Pagination
    146 - ?
    DOI
    10.3389/fonc.2012.00146
    Journal
    Front Oncol
    Metadata
    Show full item record
    Abstract
    A decade since the first evidence implicating the cell cycle transcription factor Forkhead Box M1 (FOXM1) in human tumorigenesis, a slew of subsequent studies revealed an oncogenic role of FOXM1 in the majority of human cancers including oral, nasopharynx, oropharynx, esophagus, breast, ovary, prostate, lung, liver, pancreas, kidney, colon, brain, cervix, thyroid, bladder, uterus, testis, stomach, skin, and blood. Its aberrant upregulation in almost all different cancer types suggests a fundamental role for FOXM1 in tumorigenesis. Its dose-dependent expression pattern correlated well with tumor progression starting from cancer predisposition and initiation, early premalignancy and progression, to metastatic invasion. In addition, emerging studies have demonstrated a causal link between FOXM1 and chemotherapeutic drug resistance. Despite the well-established multifaceted roles for FOXM1 in all stages of oncogenesis, its translation into clinical benefit is yet to materialize. In this contribution, I reviewed and discussed how our current knowledge on the oncogenic mechanisms of FOXM1 could be exploited for clinical use as biomarker for risk prediction, early cancer screening, molecular diagnostics/prognostics, and/or companion diagnostics for personalized cancer therapy.
    Authors
    Teh, M-T
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/11132
    Collections
    • Centre for Oral Immunobiology and Regenerative Medicine [399]
    Language
    eng
    Licence information
    CC-BY.
    Copyright statements
    © 2012 Teh.
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.